Search Results

/chemotherapy arm experienced more neutropenia and fever; however, overall, treatment discontinuations were similar in both arms: 69% of patients on the R 2 arm and 71% of those on the rituximab/chemotherapy arm completed treatment. 13 Final data showed that R 2

catheter improved significantly and albumin infusions were discontinued. She tolerated idelalisib well without any significant issues, except for one episode of mild neutropenia that resolved with temporary discontinuation of the drug. Five months into

, and hepatic function have been closely monitored throughout treatment. The patient has not experienced anemia, neutropenia, lymphopenia, or thrombocytopenia. She did experience a period of grade 1 elevation in aspartate transaminase and alanine

.3–11.8 months). 14 The main toxicity was hematologic, with 5% of patients experiencing neutropenia. A review of various cytotoxic agents studied worldwide for relapsed SCLC revealed that combination carboplatin, ifosfamide, and etoposide (CIE) yielded the

compared with docetaxel,” he said, especially with less neutropenia and alopecia. The NCCN Guidelines recommend sotorasib or adagrasib as second-line therapy options in patients with KRAS G12C mutation–positive metastatic NSCLC. 4 “So, in the second

leading to treatment discontinuation with zanubrutinib. One notable side effect of zanubrutinib was a tendency to cause more neutropenia, although this did not correlate to neutropenic fever or higher rates of grade 3 infections. “The findings of these 2

=.0005). 10 Despite these “promising” results, according to Dr. Lynch, longer-term follow-up data are needed before this regimen may be considered for integration into the NCCN Guidelines. “Notably, there is more neutropenia with N-AVD,” he added

“While under active treatment, patients with cancer are vulnerable to infection, as chemotherapy, radiation therapy, and immune-altering therapies can lead to neutropenia, lymphopenia, and altered immune competence,” commented Maria Alma Rodriguez

properties as well, according to Dr. Siefker-Radtke. She also stated that neutropenia and lymphopenia are frequently reported with agents such as gemcitabine, which could impact the ability to induce an immune response. A phase II study showed evidence of

of 4.2 months, and a median overall survival of 11.6 months. Grade 3/4 hematologic adverse events were common (neutropenia [79%], thrombocytopenia [76%], and anemia [71%]), but were clinically manageable. Nonhematologic adverse events were infrequent